Experimental Therapies: New treatments for hepatitis C including pre-clinical development that have not yet been studied in humans, and various drugs that are in phase I, II and III development to treat hepatitis C.



o       General

        445. A Pilot Study to Assess the Impact of Rosuvastatin Therapy on HCV RNA and lipid fractions in Chronic Hepatitis C Patients. (updated, May 23)

        M1794. PF-03491390, a pancaspase inhibitor, reduces aminotransferases levels and is well tolerated in patients with chronic hepatitis C (HCV). (updated, May 23)

        M1815. Rectal administration of low dose interferon alpha for patients with chronic hepatitis C led to elevation of platelet count and serum albumin level as well as suppression of viral replication. (updated, May 21)

        M1812. In Vivo Efficacy of a Fully Human Monoclonal anti-E2 Immunoglobulin in Passive Immunoprophylaxis of HCV Infection.

        M1840. Trial of oral n-acetylcysteine (NAC) to treat insulin resistance in chronic hepatitis C(HCV). (updated, May 21)


o       Celgosivir

        442. Phase II Study of celgosivir in combination with Peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype-1 non-responder patients (updated, May 28)



o       Consensus Interferon

        M1874. Consensus Interferon plus Ribavirin Therapy in Patients who are Nonresponders or Relapsers to Prior PEG IFN plus Ribavirin.

        M1877. Daily Consensus Interferon-α (CIFN) and Weight-based Ribavirin (WBR) as First-Line Therapy for HCV Patients with High Likelihood of Treatment Failure (HLTF): Interim Analysis of a Cohort.

        M1878. Outcome of Daily Consensus Interferon and Ribavirin Treatment For Patients with Chronic Hepatitis C who Failed Previous Treatments. A Single Center Experience.


o       HCV-796

        364. Favorable Cross-Resistance Profile of HCV-796 and SCH-503034 and Enhanced Anti-Replicon Activity Mediated By Combination Treatment. (updated, May 28)

        440. Pharmacodynamic Analysis of the Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796, in Combination With Pegylated Interferon Alfa-2b in Treatment-Nave Patients With Chronic HCV (updated, May 28)


o       Interferon Beta

        M1803. Feasibility of induction by twice-daily administration of interferon-beta prior to the standard combination therapy using pegylated interferon-alpha-2b plus ribavirin.


o       ITMN-191

        M1816. Characterization of HCV NS3/4A Protease Inhibition by ITMN-191 Reveals Picomolar Potency and Slow Dissociation: Implications for the Use of ITMN-191 in Chronic HCV Treatment (updated, May 24)


o       Omega Interferon

        M1798. Phase 2 Study of Omega Interferon Alone or in Combination with Ribavirin in Interferon-nave Subjects with Genotype-1 Chronic Hepatitis C (updated, May 23)


o       R1626

        M1801. Viral load and ALT reductions associated with R1626 monotherapy, a novel nucleoside analog, in chronic hepatitis C genotype 1 patients. (updated, May 23)


o       SCH-503034

        364. Favorable Cross-Resistance Profile of HCV-796 and SCH-503034 and Enhanced Anti-Replicon Activity Mediated By Combination Treatment.


o       Taribavirin (Viramidine)

        M1805. Pre-Dosing Taribavirin Prior to Combination Therapy With Pegylated Interferon Alfa-2b Versus Standard Combination Dosing: 24-Week Interim Results Examining Safety and Viral Kinetics. (updated, May 23)

        M1811. Pharmacokinetic/Pharmacodynamic (PKPD) Modeling of Hemoglobin (Hgb) in a Phase 3 Study With Taribavirin and Ribavirin in Therapy-Nave HCV Patients. (updated, May 21)


o       Telaprevir (VX-950)

        443. Predicting HCV Treatment Duration with an HCV Protease Inhibitor Co-administered with Peg-IFN/RBV by Modeling both Wild-type Virus and Low Level Resistant Variant Dynamics.


o       Valopicitabine (NM283)

        M1796. Final Results from a Phase IIA Pharmacokinetic Study of Valopicitabine (NM283) and Peg-IFNα-2b in Patients with Genotype 1 Chronic Hepatitis C.

        M1804. Valopicitabine (NM283) plus peg-interferon alfa-2a (peg-IFN) in treatment-nave patients with HCV-1 infection: preliminary results at weeks 24 and 48.